Fructosereduktion als therapeutischer Ansatz der nicht-alkoholbedingten Fettlebererkrankung (NAFLD) beim Menschen
Valentina Volynets(University of Hohenheim), Ina Bergheim(University of Vienna), MA Küper(Universitätsklinikum Tübingen), A Köngisrainer(Universitätsklinikum Tübingen), IB Maier(University of Hohenheim), Jürgen Machann(University Children's Hospital Tübingen), SC Bischoff(University of Hohenheim), Astrid Spruss(University of Hohenheim)
Cited by 0
Related Papers
Toll-Like Receptor 4 Is Involved in the Development of Fructose-Induced Hepatic Steatosis in Mice†
|Hepatology|2009|557
Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
|Digestive Diseases and Sciences|2012|259
Metformin Prevents Alcohol-Induced Liver Injury in the Mouse: Critical Role of Plasminogen Activator Inhibitor-1
|Gastroenterology|2006|205
Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time
|The Journal of Nutritional Biochemistry|2015|181
Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function
|Laboratory Investigation|2012|164